All In Biotech

Drug Trial Radar · NCT06625060

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 670 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

670

Actual

Start

Oct 10, 2024

Primary completion

Oct 31, 2027

Study completion Oct 31, 2027

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Oct 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. Corabotase (also known as IPN10200) is a medication that stops the release of these chemical messengers. Participants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. "Headache days" are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. "Migraine days" occur when the headache displays clear migraine characteristics. This study aims to determine: * The safety and efficacy of injecting Corabotase directly into the muscles of the head and neck to prevent EM and CM, * The right amount (dose) of Corabotase to inject at each point, * The total amount (dose) of Corabotase that provides the best balance between safety and efficacy preventing migraines. Participants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks.

Conditions

  • Episodic Migraine
  • Chronic Migraine

Interventions

  • CorabotaseBiological

    Lyophilised powder

  • PlaceboOther

    Excipients without active substance, Lyophilised powder

  • Corabotase dose ABiological

    Lyophilised powder

  • Corabotase dose BBiological

    Lyophilised powder

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants experiencing any Adverse Event (AEs) including treatment emergent adverse events (TEAEs), serious adverse events (SAEs), adverse event of special interest (AESI) and AE leading to treatment discontinuationTime frame: For step 1: From baseline until end of study at Week 36
  2. Percentage of Participants with clinically significant changes from baseline in Laboratory ParametersTime frame: For step 1: At all timepoints post injection until Week 36
  3. Percentage of Participants With Clinically Significant Changes from baseline in Vital SignsTime frame: For step 1: At all timepoints post injection until Week 36
  4. Percentage of participants with clinically significant change from baseline in facial examinationTime frame: For step 1: At all timepoints post injection until Week 36
  5. Percentage of participants with clinically significant change from baseline in 12-lead Electrocardiogram (ECG) readingsTime frame: For step 1: At all timepoints post injection until Week 36
  6. Treatment-emergence of suicidal ideation/suicidal behaviourTime frame: For step 1: At all timepoints post injection until Week 36
  7. Percentage of participants with Binding antibodies to IPN10200Time frame: For step 1: At baseline, Week 4, Week 12 and Week 36.
  8. Percentage of participants with neutralising antibodies to IPN10200Time frame: For step 1: At baseline, Week 4, Week 12 and Week 36.
  9. Change from baseline in the number of Monthly migraine days (MMD)sTime frame: For step 2: At Week 12 (Weeks 9-12).

Locations

162 sites in 14 countries. Site status is shown where the registry gives one.

  • Central Research Associates

    Birmingham, Alabama

  • Rehabilitation & Neurological Services, LLC

    Huntsville, Alabama

  • MD First Research - Chandler - Neurology

    Chandler, Arizona

  • MD First Research - Chandler

    Chandler, Arizona

  • Axiom Research, LLC

    Apple Valley, California

  • Profound Research. LLC - NCSC

    Carlsbad, California

  • M3Wake -PRI Encino

    Encino, California

  • WR-PRI Encino

    Encino, California

  • Neuro-Pain Medical Center

    Fresno, California

  • Fullerton Neurological Center - Neurology

    Fullerton, California

  • Neurology Center of North Orange County

    Fullerton, California

  • Kaizen Brain Center

    La Jolla, California

  • Pharmacology Research Institute (PRI)

    Los Alamitos, California

  • Pharmacology Research Institute (PRI) - Los Alamitos/Long Beach

    Newport Beach, California

  • Profound Research, LLC

    Pasadena, California

  • Acclaim Clinical Research - Internal Medicine

    San Diego, California

  • Clinical Trials Management LLC

    Thousand Oaks, California

  • Alliance Clinical West Hills (Focus Clinical Research)

    West Hills, California

  • Advanced Neuroscience Research Center, LLC

    Fort Collins, Colorado

  • Advanced Neuroscience Research Center, LLC - Neurology

    Fort Collins, Colorado

  • New England Institute for Neurology and Headache (NEINH)/Medical Practice

    Stamford, Connecticut

  • Neurology Offices

    Boca Raton, Florida

  • AGA Clinical Trials

    Hialeah, Florida

  • M3 Wake Research/MSRA, LLC

    Lake City, Florida

  • M3 Wake Research/MSRA,LLC

    Lake City, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • Emerald Coast Center For Neurological Disorders

    Pensacola, Florida

  • Conquest Research

    Winter Park, Florida

  • NeuroTrials Research, Inc.

    Atlanta, Georgia

  • Crescent City Headache and Neurology Center, LLC

    Chalmette, Louisiana

  • Ochsner Health Center - Covington

    Covington, Louisiana

  • DelRicht Research

    New Orleans, Louisiana

  • DelRicht Research at Touro Medical Center

    New Orleans, Louisiana

  • LSU Healthcare Network Orthopedic & Sports Medicine

    New Orleans, Louisiana

  • MedStar Neurosciences and Rehabilitation Research Network

    Baltimore, Maryland

  • MedStar Neurosciences and Rehabilitation

    Baltimore, Maryland

  • MedStar Franklin Square Hospital Center

    Baltimore, Maryland

  • Medstar Franklin Square Medical Center

    Baltimore, Maryland

  • Neurology Center of NE,PC - Neurology

    Foxborough, Massachusetts

Showing 40 of 162 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.